within Pharmacolibrary.Drugs.ATC.B;

model B06AB01
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0006333333333333333,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0034,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B06AB01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Hemin is an iron-containing metalloporphyrin used primarily for the treatment of acute intermittent porphyria and related acute porphyrias. It is administered as a heme replacement to suppress the hepatic production of porphyrin precursors. Hemin is currently approved for medical use by major regulatory agencies such as FDA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adult patients with acute intermittent porphyria, following intravenous administration. Published clinical PK data for hemin are limited; the following values are estimated based on sparse literature and product information.</p><h4>References</h4><ol><li><p>Syed, YY (2021). Givosiran: A Review in Acute Hepatic Porphyria. <i>Drugs</i> 81(7) 841–848. DOI:<a href=&quot;https://doi.org/10.1007/s40265-021-01511-3&quot;>10.1007/s40265-021-01511-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33871817/&quot;>https://pubmed.ncbi.nlm.nih.gov/33871817</a></p></li><li><p>Siegert, SW, &amp; Holt, RJ (2008). Physicochemical properties, pharmacokinetics, and pharmacodynamics of intravenous hematin: a literature review. <i>Advances in therapy</i> 25(9) 842–857. DOI:<a href=&quot;https://doi.org/10.1007/s12325-008-0094-y&quot;>10.1007/s12325-008-0094-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18777015/&quot;>https://pubmed.ncbi.nlm.nih.gov/18777015</a></p></li><li><p>Habtezion, A, et al., &amp; Omary, MB (2011). Panhematin provides a therapeutic benefit in experimental pancreatitis. <i>Gut</i> 60(5) 671–679. DOI:<a href=&quot;https://doi.org/10.1136/gut.2010.217208&quot;>10.1136/gut.2010.217208</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21159893/&quot;>https://pubmed.ncbi.nlm.nih.gov/21159893</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B06AB01;
